Arcellx (NASDAQ:ACLX) Posts Quarterly Earnings Results, Meets Expectations

Arcellx (NASDAQ:ACLX) announced its quarterly earnings results on Thursday. The company reported ($1.01) EPS for the quarter, meeting analysts’ consensus estimates of ($1.01), FiscalAI reports. The firm had revenue of $1.65 million during the quarter, compared to the consensus estimate of $13.40 million. Arcellx had a negative net margin of 607.01% and a negative return on equity of 51.13%.

Arcellx Trading Up 0.1%

Shares of NASDAQ ACLX traded up $0.12 during mid-day trading on Thursday, reaching $113.88. The company had a trading volume of 11,617,048 shares, compared to its average volume of 2,676,067. The stock has a market cap of $6.58 billion, a price-to-earnings ratio of -28.98 and a beta of 0.36. Arcellx has a 52 week low of $47.86 and a 52 week high of $114.26. The business’s 50-day moving average is $69.82 and its 200-day moving average is $75.65.

Insiders Place Their Bets

In other news, insider Christopher Heery sold 5,882 shares of the firm’s stock in a transaction that occurred on Wednesday, January 14th. The shares were sold at an average price of $68.51, for a total transaction of $402,975.82. Following the transaction, the insider directly owned 23,749 shares of the company’s stock, valued at approximately $1,627,043.99. This trade represents a 19.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last three months, insiders have sold 19,450 shares of company stock worth $1,283,477. Company insiders own 8.35% of the company’s stock.

Institutional Trading of Arcellx

A number of large investors have recently modified their holdings of the company. State of Wyoming bought a new position in Arcellx in the second quarter worth approximately $28,000. US Bancorp DE lifted its holdings in shares of Arcellx by 57.2% in the 3rd quarter. US Bancorp DE now owns 1,797 shares of the company’s stock worth $148,000 after buying an additional 654 shares during the period. Man Group plc bought a new position in shares of Arcellx during the 4th quarter worth $217,000. Sei Investments Co. bought a new position in shares of Arcellx during the 3rd quarter worth $238,000. Finally, Virtus Investment Advisers LLC increased its stake in shares of Arcellx by 116.3% during the fourth quarter. Virtus Investment Advisers LLC now owns 3,701 shares of the company’s stock valued at $241,000 after buying an additional 1,990 shares during the period. Hedge funds and other institutional investors own 96.03% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on ACLX. Guggenheim downgraded Arcellx from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $120.00 to $115.00 in a research report on Wednesday. Leerink Partners restated a “market perform” rating and set a $115.00 price target on shares of Arcellx in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcellx in a research note on Wednesday, January 21st. UBS Group cut shares of Arcellx from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $100.00 to $115.00 in a research report on Tuesday. Finally, Rothschild & Co Redburn downgraded shares of Arcellx from a “buy” rating to a “neutral” rating and set a $82.00 target price on the stock. in a research note on Thursday, February 12th. One equities research analyst has rated the stock with a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $111.87.

Trending Headlines about Arcellx

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Heavy trading and momentum: Shares are trading with much higher-than-normal volume and are near a 52-week high, suggesting momentum, investor interest, or short-covering as a key driver. Read More.
• Neutral Sentiment: FY2030 earnings forecast released by HC Wainwright — the note provides updated forward estimates but the publicly available summary doesn’t point to a clear directional catalyst; investors should read the full note for assumptions. Read More.
• Neutral Sentiment: Short-interest data shown in the feed is inconsistent/zeroed (reported as 0 shares and NaN change); unreliable short-interest reporting makes it hard to quantify squeeze risk from these figures alone. (Internal trading/short data entry)
• Negative Sentiment: UBS downgraded ACLX — another analyst cut that increases selling pressure and raises questions about near-term expectations. Read More.
• Negative Sentiment: Citigroup downgraded ACLX — part of a cluster of big-shop downgrades that can weigh on sentiment and liquidity for the stock. Read More.
• Negative Sentiment: Multiple firms have cut ratings to Hold (Robert W. Baird, Canaccord Genuity, Needham, Wells Fargo, Evercore, Leerink Partners), signaling a broad pullback in sell-side conviction that could limit further upside until new fundamental data arrives. Read More. Read More. Read More. Read More. Read More.

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.